Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer.
BioLite, Inc.
BioLite, Inc.
Bristol-Myers Squibb
Beijing Biotech
Genmab
Cantargia AB
Beijing Biotech
Radiopharm Theranostics, Ltd
Beijing Biotech
Bristol-Myers Squibb
AstraZeneca
Eisai Inc.
PMV Pharmaceuticals, Inc
AstraZeneca
NeoImmuneTech
Tubulis GmbH
Sumitomo Pharma America, Inc.
Genmab
NEC Bio B.V
Exscientia AI Limited
Shenzhen Majory Biotechnology Co., Ltd.
Nanjing Leads Biolabs Co.,Ltd
Amgen
AstraZeneca
Gilead Sciences
Onchilles Pharma Inc
Ocellaris Pharma, Inc.
Jacobio Pharmaceuticals Co., Ltd.
Apollo Therapeutics Ltd
Seagen Inc.
Transgene
Avenzo Therapeutics, Inc.
BicycleTx Limited
Pfizer
BicycleTx Limited
Volastra Therapeutics, Inc.
Strand Therapeutics Inc.
ITM Oncologics GmbH
Immunitas Therapeutics
Scancell Ltd
CytoDyn, Inc.
A2 Biotherapeutics Inc.
TCR2 Therapeutics
Incyte Corporation
ProDa BioTech, LLC
MacroGenics
Hutchmed
Medicenna Therapeutics, Inc.
TransThera Sciences (Nanjing), Inc.
Formation Biologics
Bristol-Myers Squibb